Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 15/20 | 0.55 |
| ▸ | HTR1B | P28222 | 15/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938670 | 0.87 | HTR1A (0.72) | HTR2CHTR1AHTR1DHTR1BCYP2D6 | |
| SCHEMBL8783731 | 0.84 | HTR1A (1.00) | HTR2CHTR1AHTR1DHTR1BCYP2D6 | |
| SCHEMBL9077790 | 0.82 | HTR1D (0.68) | HTR2CHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL8662568 | 0.79 | HTR1D (0.71) | HTR2CHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL8805258 | 0.79 | HTR1D (0.70) | HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL7480727 | 0.79 | HTR1D (0.70) | HTR2CHTR1DHTR1B | |
| SCHEMBL4344147 | 0.78 | HTR1D (0.73) | HTR2CHTR1AHTR1DHTR1BCYP2D6 | |
| SCHEMBL8659017 | 0.77 | HTR1D (0.63) | HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL4579559 | 0.77 | HTR1D (0.54) | HTR2CHTR1AHTR1DHTR1BCYP2D6 | |
| SCHEMBL7471152 | 0.75 | HTR1D (0.73) | HTR2CHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796675-A4 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1796675-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006039252-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | HTR2C 4375/4885HTR1A 3110/4885HTR1D 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.